1,534 reports of this reaction
6.5% of all VEMURAFENIB reports
#1 most reported adverse reaction
RASH is the #1 most commonly reported adverse reaction for VEMURAFENIB, manufactured by Genentech, Inc.. There are 1,534 FDA adverse event reports linking VEMURAFENIB to RASH. This represents approximately 6.5% of all 23,551 adverse event reports for this drug.
Patients taking VEMURAFENIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is moderately reported among VEMURAFENIB users, representing a notable but not dominant share of adverse events.
In addition to rash, the following adverse reactions have been reported for VEMURAFENIB:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 1,534 FDA reports for VEMURAFENIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 6.5% of all adverse event reports for VEMURAFENIB, making it one of the most commonly reported side effect.
If you experience rash while taking VEMURAFENIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.